The company intends to use the funding to continue to develop and commercialize its non-invasive prenatal diagnostic for Down syndrome and other genetic conditions. This includes the expansion of the NIH-funded clinical trial and preparing for commercial launch of the test in 2012.

Led by CEO Matthew Rabinowitz, Ph.D., Natera has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA – as small as that from a single cell.
Test offerings include:
- preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children;
- products of conception testing following miscarriage to extensively analyze fetal chromosomes in order to understand the cause; and
- non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother’s blood drawn in the first trimester.
Non-invasive testing for paternity is currently available worldwide.